|
1
|
Dinkic C, Jahn F, Zygmunt M, Schuetz F,
Rom J, Sohn C and Fluhr H: PARP inhibition sensitizes endometrial
cancer cells to paclitaxel-induced apoptosis. Oncol Lett.
13:2847–2851. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Oki S, Sone K, Oda K, Hamamoto R, Ikemura
M, Maeda D, Takeuchi M, Tanikawa M, Mori-Uchino M, Nagasaka K, et
al: Oncogenic histone methyltransferase EZH2: A novel prognostic
marker with therapeutic potential in endometrial cancer.
Oncotarget. 8:40402–40411. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ray M and Fleming G: Management of
advanced-stage and recurrent endometrial cancer. Semin Oncol.
36:145–154. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Abdelazeem KNM, Singh Y, Lang F and Salker
MS: Negative effect of ellagic acid on cytosolic pH regulation and
glycolytic flux in human endometrial cancer cells. Cell Physiol
Biochem. 41:2374–2382. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zheng S, Jia Q, Shen H, Xu X, Ling J, Jing
C and Zhang B: Treatment with the herbal formula Songyou Yin
inhibits epithelial-mesenchymal transition in hepatocellular
carcinoma through downregulation of TGF-β1 expression and
inhibition of the SMAD2/3 signaling pathway. Oncol Lett.
13:2309–2315. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Luan X, Ma C, Wang P and Lou F: HMGB1 is
negatively correlated with the development of endometrial carcinoma
and prevents cancer cell invasion and metastasis by inhibiting the
process of epithelial-to-mesenchymal transition. Onco Targets Ther.
10:1389–1402. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
van Esterik M, Van Gool IC, de Kroon CD,
Nout RA, Creutzberg CL, Smit VTHBM, Bosse T and Stelloo E: Limited
impact of intratumour heterogeneity on molecular risk assignment in
endometrial cancer. Oncotarget. 8:25542–25551. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tang YL, Zhu LY, Li Y, Yu J, Wang J, Zeng
XX, Hu KX, Liu JY and Xu JX: Metformin use is associated with
reduced incidence and improved survival of endometrial cancer: A
meta-analysis. Biomed Res Int. 2017:59053842017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dou L, Wang S, Sun L, Huang X, Zhang Y,
Shen T, Guo J, Man Y, Tang W and Li J: Mir-338-3p mediates
Tnf-A-induced hepatic insulin resistance by targeting PP4r1 to
regulate PP4 expression. Cell Physiol Biochem. 41:2419–2431. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chiofalo B, Laganà AS, Vaiarelli A, La
Rosa VL, Rossetti D, Palmara V, Valenti G, Rapisarda AMC, Granese
R, Sapia F, et al: Do miRNAs play a role in fetal growth
restriction? A fresh look to a busy corner. Biomed Res Int.
2017:60731672017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Meeuwsen JAL, van T Hof FNG, van Rheenen
W, Rinkel GJE, Veldink JH and Ruigrok YM: Circulating microRNAs in
patients with intracranial aneurysms. PLoS One. 12:e01765582017.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li M, Gu K, Liu W, Xie X and Huang X:
MicroRNA-200c as a prognostic and sensitivity marker for platinum
chemotherapy in advanced gastric cancer. Oncotarget. 8:51190–51199.
2017.PubMed/NCBI
|
|
13
|
Miao F, Zhu J, Chen Y, Tang N, Wang X and
Li X: MicroRNA-183-5p romotes the proliferation, invasion and
metastasis of human pancreatic adenocarcinoma cells. Oncol Lett.
11:134–140. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang J, Wang X, Li Z, Liu H and Teng Y:
MicroRNA-183 suppresses retinoblastoma cell growth, invasion and
migration by targeting LRP6. FEBS J. 281:1355–1365. 2014.
View Article : Google Scholar
|
|
15
|
Zhong GX, Feng SD, Shen R, Wu ZY, Chen F
and Zhu X: The clinical significance of the Ezrin gene and
circulating tumor cells in osteosarcoma. Onco Targets Ther.
10:527–533. 2017. View Article : Google Scholar :
|
|
16
|
Cao LL, Xie JW, Lin Y, Zheng CH, Li P,
Wang JB, Lin JX, Lu J, Chen QY and Huang CM: miR-183 inhibits
invasion of gastric cancer by targeting Ezrin. Int J Clin Exp
Pathol. 7:5582–5594. 2014.PubMed/NCBI
|
|
17
|
Wang HJ and Zheng WX: Precursor lesions of
type II endometrial cancer: Diagnostic criteria and pathogenesis.
Zhonghua Bing Li Xue Za Zhi. 36:505–507. 2007.In Chinese.
PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
19
|
Huang Y, Ye Y, Long P, Zhao S, Zhang L and
A Y: Silencing of CXCR4 and CXCR7 expression by RNA interference
suppresses human endometrial carcinoma growth in vivo. Am J Transl
Res. 9:1896–1904. 2017.
|
|
20
|
Ma YJ, Ha CF, Bai ZM, Li HN, Xiong Y and
Jiang J: Overexpression of microRNA-205 predicts lymph node
metastasis and indicates an unfavorable prognosis in endometrial
cancer. Oncol Lett. 12:4403–4410. 2016. View Article : Google Scholar
|
|
21
|
Tang JF, Yu ZH, Liu T, Lin ZY, Wang YH,
Yang LW, He HJ, Cao J, Huang HL and Liu G: Five miRNAs as novel
diagnostic biomarker candidates for primary nasopharyngeal
carcinoma. Asian Pac J Cancer Prev. 15:7575–7581. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhu J, Feng Y, Ke Z, Yang Z, Zhou J, Huang
X and Wang L: Down-regulation of miR-183 promotes migration and
invasion of osteosarcoma by targeting Ezrin. Am J Pathol.
180:2440–2451. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ghaffari A, Hoskin V, Szeto A, Hum M,
Liaghati N, Nakatsu K, LeBrun D, Madarnas Y, Sengupta S and Elliott
BE: A novel role for ezrin in breast cancer
angio/lymphangiogenesis. Breast Cancer Res. 16:4382014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li J, Wei K, Yu H, Jin D, Wang G and Yu B:
Prognostic value of Ezrin in various cancers: A Systematic review
and updated meta-analysis. Sci Rep. 5:179032015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li M, Feng YM and Fang SQ: Overexpression
of ezrin and galectin-3 as predictors of poor prognosis of cervical
cancer. Braz J Med Biol Res. 50:e53562017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Andersson G, Wennersten C, Gaber A, Boman
K, Nodin B, Uhlén M, Segersten U, Malmström PU and Jirström K:
Reduced expression of ezrin in urothelial bladder cancer signifies
more advanced tumours and an impaired survival: Validatory study of
two independent patient cohorts. BMC Urol. 14:362014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li CL, Yang D, Cao X, Wang F, Hong DY,
Wang J, Shen XC and Chen Y: Fibronectin induces
epithelial-mesenchymal transition in human breast cancer MCF-7
cells via activation of calpain. Oncol Lett. 13:3889–3895. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang C, Xu X, Jin H and Liu G: Nicotine
may promote tongue squamous cell carcinoma progression by
activating the Wnt/β-catenin and Wnt/PCP signaling pathways. Oncol
Lett. 13:3479–3486. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Oba S, Mizutani T, Suzuki E, Nishimatsu H,
Takahashi M, Ogawa Y, Kimura K, Hirata Y and Fujita T: A useful
method of identifying of miRNAs which can down-regulate Zeb-2. BMC
Res Notes. 6:4702013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhao H, Guo M, Zhao G, Ma Q, Ma B, Qiu X
and Fan Q: miR-183 inhibits the metastasis of osteosarcoma via
downregulation of the expression of Ezrin in F5M2 cells. Int J Mol
Med. 30:1013–1020. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lowery AJ, Miller N, Dwyer RM and Kerin
MJ: Dysregulated miR-183 inhibits migration in breast cancer cells.
BMC Cancer. 10:5022010. View Article : Google Scholar : PubMed/NCBI
|
